217 related articles for article (PubMed ID: 27665844)
1. Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First study.
Hagihara M; Iriyama N; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
Oncol Rep; 2016 Nov; 36(5):2976-2982. PubMed ID: 27665844
[TBL] [Abstract][Full Text] [Related]
2. Lymphocytosis after treatment with dasatinib in chronic myeloid leukemia: Effects on response and toxicity.
Schiffer CA; Cortes JE; Hochhaus A; Saglio G; le Coutre P; Porkka K; Mustjoki S; Mohamed H; Shah NP
Cancer; 2016 May; 122(9):1398-407. PubMed ID: 26998677
[TBL] [Abstract][Full Text] [Related]
3. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
[TBL] [Abstract][Full Text] [Related]
4. Chronic myeloid leukemia patients who develop grade I/II pleural effusion under second-line dasatinib have better responses and outcomes than patients without pleural effusion.
Eskazan AE; Eyice D; Kurt EA; Elverdi T; Yalniz FF; Salihoglu A; Ar MC; Ongoren Aydin S; Baslar Z; Ferhanoglu B; Aydin Y; Tuzuner N; Ozbek U; Soysal T
Leuk Res; 2014 Jul; 38(7):781-7. PubMed ID: 24832371
[TBL] [Abstract][Full Text] [Related]
5. Clinical Efficacy and Safety of First-Line Dasatinib Therapy and the Relevance of Velocity of BCR-ABL1 Transcript Decline for Achievement of Molecular Responses in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Report from the Juntendo Yamanashi Cooperative Study Group.
Takaku T; Iriyama N; Mitsumori T; Sato E; Gotoh A; Kirito K; Noguchi M; Koike M; Sakamoto J; Oba K; Komatsu N
Oncology; 2018; 94(2):85-91. PubMed ID: 29151104
[TBL] [Abstract][Full Text] [Related]
6. Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series.
Iurlo A; Galimberti S; Abruzzese E; Annunziata M; Bonifacio M; Latagliata R; Pregno P; Ferrero D; Sorà F; Orlandi EM; Fava C; Cattaneo D; Bucelli C; Binotto G; Pungolino E; Tiribelli M; Gozzini A; Gugliotta G; Castagnetti F; Stagno F; Rege-Cambrin G; Martino B; Luciano L; Breccia M; Sica S; Bocchia M; Pane F; Saglio G; Rosti G; Specchia G; Cortelezzi A; Baccarani M
Ann Hematol; 2018 Jan; 97(1):95-100. PubMed ID: 28971265
[TBL] [Abstract][Full Text] [Related]
7. Early results of lower dose dasatinib (50 mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia.
Naqvi K; Jabbour E; Skinner J; Yilmaz M; Ferrajoli A; Bose P; Thompson P; Alvarado Y; Jain N; Takahashi K; Burger J; Estrov Z; Borthakur G; Pemmaraju N; Paul S; Cortes J; Kantarjian HM
Cancer; 2018 Jul; 124(13):2740-2747. PubMed ID: 29723397
[TBL] [Abstract][Full Text] [Related]
8. Incidence of pleural effusion with dasatinib and the effect of switching therapy to a different TKI in patients with chronic phase CML.
Jain AG; Gesiotto Q; Ball S; Nodzon L; Rodriguez A; Chan O; Padron E; Kuykendall A; Komrokji R; Sallman DA; Lancet JE; Pinilla-Ibarz J; Sweet K
Ann Hematol; 2024 Jun; 103(6):1941-1945. PubMed ID: 38634915
[TBL] [Abstract][Full Text] [Related]
9. Long-term follow-up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic-phase chronic myeloid leukemia.
Naqvi K; Jabbour E; Skinner J; Anderson K; Dellasala S; Yilmaz M; Ferrajoli A; Bose P; Thompson P; Alvarado Y; Jain N; Takahashi K; Burger J; Estrov Z; Borthakur G; Pemmaraju N; Paul S; Cortes J; Kantarjian HM
Cancer; 2020 Jan; 126(1):67-75. PubMed ID: 31553487
[TBL] [Abstract][Full Text] [Related]
10. Dasatinib in imatinib-resistant or -intolerant chronic-phase, chronic myeloid leukemia patients: 7-year follow-up of study CA180-034.
Shah NP; Rousselot P; Schiffer C; Rea D; Cortes JE; Milone J; Mohamed H; Healey D; Kantarjian H; Hochhaus A; Saglio G
Am J Hematol; 2016 Sep; 91(9):869-74. PubMed ID: 27192969
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
[TBL] [Abstract][Full Text] [Related]
12. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
13. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
Quintás-Cardama A; Kantarjian H; O'brien S; Borthakur G; Bruzzi J; Munden R; Cortes J
J Clin Oncol; 2007 Sep; 25(25):3908-14. PubMed ID: 17761974
[TBL] [Abstract][Full Text] [Related]
14. Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first study.
Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
Am J Hematol; 2015 Sep; 90(9):819-24. PubMed ID: 26103598
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Generic Dasatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase: A Multicenter Prospective Study in China.
Yu W; Du X; Wang W; Lou J; Liu P; Meng L; Jin J
Clin Lymphoma Myeloma Leuk; 2022 Sep; 22(9):e867-e873. PubMed ID: 35842355
[TBL] [Abstract][Full Text] [Related]
16. Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study group.
Iriyama N; Fujisawa S; Yoshida C; Wakita H; Chiba S; Okamoto S; Kawakami K; Takezako N; Kumagai T; Inokuchi K; Ohyashiki K; Taguchi J; Yano S; Igarashi T; Kouzai Y; Morita S; Sakamoto J; Sakamaki H
Am J Hematol; 2015 Apr; 90(4):282-7. PubMed ID: 25530131
[TBL] [Abstract][Full Text] [Related]
17. Four-year follow-up of patients with imatinib-resistant or intolerant chronic myeloid leukemia receiving dasatinib: efficacy and safety.
Huang X; Jiang Q; Hu J; Li J; Jin J; Meng F; Shen Z; Liu T; Wu D; Wang J; Wang J
Front Med; 2019 Jun; 13(3):344-353. PubMed ID: 30159669
[TBL] [Abstract][Full Text] [Related]
18. Management and Risk Factors for Pleural Effusion in Japanese Patients with Chronic Myeloid Leukemia Treated with First-line Dasatinib in Real-world Clinical Practice.
Tsuchiya S; Takaku T; Watanabe N; Iriyama N; Kimura Y; Iwanaga E; Sugimoto KJ; Mitsumori T; Ishikawa M; Nakazato T; Fujita H; Sato E; Hatta Y; Asou N; Kizaki M; Tokuhira M; Ando M; Kawaguchi T
Intern Med; 2023 Nov; 62(22):3299-3303. PubMed ID: 37005261
[TBL] [Abstract][Full Text] [Related]
19. Development of a human herpesvirus 8-negative effusion-based lymphoma during treatment with dasatinib for chronic myeloid leukemia.
Suyama T; Hagihara M; Matsui N; Irie R; Osamura Y; Sakai T; Watanabe S; Umemoto S; Miyao N
J Clin Exp Hematop; 2023 Mar; 63(1):43-48. PubMed ID: 36843069
[TBL] [Abstract][Full Text] [Related]
20. Rapid reduction in BCR-ABL1 transcript predicts deep molecular response in dasatinib-treated chronic-phase chronic myeloid leukaemia patients.
Murai K; Yamaguchi K; Ito S; Miyagishima T; Shindo M; Wakasa K; Inomata M; Nagashima T; Kondo T; Fujimoto N; Yamamoto S; Yonezumi M; Oyake T; Kowata S; Tsukushi Y; Mine T; Meguro K; Ikeda K; Watanabe R; Saito S; Sato S; Tajima K; Chou T; Kubo K; Oba K; Sakamoto J; Ishida Y;
Eur J Haematol; 2018 Jan; 100(1):27-35. PubMed ID: 28895203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]